Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flunoxaprofen
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flunoxaprofen is a chiral nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class, structurally related to naproxen. It was developed for the treatment of osteoarthritis and rheumatoid arthritis, showing comparable or superior anti-inflammatory activity to other NSAIDs such as indomethacin and ibuprofen. Unlike many NSAIDs, flunoxaprofen primarily inhibits leukotriene synthesis rather than prostaglandin synthesis and does not significantly inhibit gastric cyclooxygenase activity, which may reduce gastrointestinal side effects. However, its clinical use was discontinued due to concerns about hepatotoxicity[1][3][4][5]. The drug acts as a protein kinase C agonist in addition to its anti-inflammatory properties[1].
- Brand names
- Priaxim
- Other names
- flunoxaprofenoFlunoxaprofenum
02
Targets
PKC (Protein kinase C family)COX
Beyond the preview
Go deeper on Flunoxaprofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flunoxaprofen.